Abvc Biopharma (ABVC) Receivables - Net (2012 - 2024)
Abvc Biopharma's (ABVC) quarterly Receivables - Net came in at $1529.0 in Q3 2024, little changed YoY from $1530.0 in Q4 2023, and little changed on a QoQ basis from $1530.0 in Q2 2024.
Abvc Biopharma (ABVC) Receivables - Net (2012 - 2024) Analysis & Trends
Abvc Biopharma (ABVC) has 9 years of Receivables - Net data on file, last reported at $1529.0 in Q3 2024.
- Quarterly Receivables - Net changed 0.07% year-over-year to $1529.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $1529.0 (changed 0.07% YoY) and the FY2023 annual result came in at $839983.0, up 10.91% from the prior year.
- Receivables - Net was little changed at $1529.0 in Q3 2024, from $1530.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $839983.0 in Q4 2023 to a low of $1529.0 in Q3 2024.
- A 5-year average of $225176.7 and a median of $159712.0 in 2020 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2021 — Receivables - Net surged 256.14% — and 2024, when it sank 98.77%.
- Tracing ABVC's Receivables - Net over 5 years: stood at $159712.0 in 2020, then soared by 75.75% to $280692.0 in 2021, then jumped by 169.81% to $757343.0 in 2022, then gained by 10.91% to $839983.0 in 2023, then plunged by 99.82% to $1529.0 in 2024.
- The last three Receivables - Net figures came in at $1529.0 (Q3 2024), $1530.0 (Q2 2024), and $1530.0 (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - |
| 10 | Abvc Biopharma | 24.23 Mn | 24.23 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 1,529.00 |
| Sep 30, 2024 | 1,529.00 |
| Jun 30, 2024 | 1,530.00 |
| Jun 30, 2024 | 1,530.00 |
| Mar 31, 2024 | 1,530.00 |
| Mar 31, 2024 | 1,530.00 |
| Dec 31, 2023 | 839,983.00 |
| Dec 31, 2023 | 839,983.00 |
| Sep 30, 2023 | 1,530.00 |
| Sep 30, 2023 | 1,530.00 |
| Jun 30, 2023 | 12,358.00 |
| Jun 30, 2023 | 12,358.00 |
| Mar 31, 2023 | 124,133.00 |
| Mar 31, 2023 | 124,133.00 |
| Dec 31, 2022 | 757,343.00 |
| Dec 31, 2022 | 757,343.00 |
| Sep 30, 2022 | 47,680.00 |
| Sep 30, 2022 | 47,680.00 |
| Jun 30, 2022 | 289,474.00 |
| Jun 30, 2022 | 289,474.00 |